ArticleApplied health economics and health policy2022
Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
Article in Applied health economics and health policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Willingness to Pay per QALY: A Systematic Review of Demand-Side Valuations with a Focus on Age and Disease Severity.Applied health economics and health policy · 2026Pooled it
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.Human vaccines & immunotherapeutics · 2026Article
- Assessment of cost-effectiveness threshold using a double-bounded dichotomous choice model.Public health in practice (Oxford, England) · 2026Article
- Comparison of survival outcomes between kidney transplant and dialysis in patients with previous cancer.Chinese medical journal · 2026Observational
- Monetary evaluation of quality-adjusted life year in patients with malignant tumor in China: Willingness-to-pay analysis.Medicine · 2026Article
- Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis.Frontiers in pharmacology · 2026Article
- Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China.Applied health economics and health policy · 2025Article
- How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study.Global health research and policy · 2025Article
- Valuing health across groups: a cross-sectional population-based willingness-to-pay survey in Bhutan.BMJ global health · 2025Article
- Patient willingness to pay and preference for cervical cancer treatments among middle- and low-income populations in Xinjiang.Journal of patient-reported outcomes · 2025Article
- Novel biomarker panel combined with imaging parameters for predicting cardiovascular complications in diabetic patients: a retrospective cohort study.BMC cardiovascular disorders · 2025Article
- Cost-utility analysis of a tiered diagnostic approach combining a screening model and polysomnography in pediatric obstructive sleep apnea.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Evaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard Peripheral Insertion Central Catheters in Patients with Hematologic Disease: A Health Economic Analysis.International journal of environmental research and public health · 2025Article
- A cost-effectiveness analysis of baloxavir marboxil versus oseltamivir for seasonal influenza treatment in China.Frontiers in pharmacology · 2025Article
- Article
- QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.BMJ global health · 2024Article
- Projections of Socioeconomic Costs for Individuals with Dementia in China 2020-2050: Modeling Study.Journal of Alzheimer's disease : JAD · 2024Article
- Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.Cost effectiveness and resource allocation : C/E · 2023Article
- Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to estimate the population's willingness to pay (WTP) for an additional quality-adjusted life-year (QALY) in China.
methodsThe WTP for an additional QALY (WTP/Q) was estimated using a contingent valuation survey with quota sampling and snowball sampling, using a pre-designed questionnaire with 18 hypothetical scenarios. The change in health state was depicted by the EQ-5D-5L. The questionnaires were completed by telephone and face-to-face interviews. Two-part regression models were used to test validity and how different factors affect WTP/Q.
resultsA total of 2008 people participated in this survey and provided 3265 WTP responses for further analysis. The average WTP/Q for the entire sample is 113,120 Renminbi (RMB) (USD 16,884), which is 1.75 times the gross domestic product (GDP) per capita. For the quality-of-life improvement scenarios, the mean WTP/Q is RMB 78,907 (USD 11,777, 1.22 times GDP per capita), which is significantly lower than the life extension scenarios (RMB 177,761, USD 26,531, 2.76 times GDP per capita). Age was found to be negatively related to positive WTP. Educational level was positively related to the probability of reporting positive WTP and the level of WTP/Q. Although the EQ-5D-5L utility scores of respondents did not prove to be statistically significant determinants of WTP/Q, the two dimensions of EQ-5D-5L, pain/discomfort and anxiety/depression, had an impact on WTP/Q. In addition, WTP/Q was higher when the health outcome had a 50% probability of occurring than when the health outcome was 100% certain. WTP/Q was higher when a lower health gain was presented to the respondent.
conclusionThis study provides empirical evidence of the monetary value of an additional QALY from a sample of the Chinese population. In addition, a higher threshold for end-of-life therapies should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.